Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects
Acta Pharmaceutica Sinica B · 2024-01 · 14 (1) · 155-169
DOI: 10.1016/j.apsb.2023.08.017 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Acta Pharmaceutica Sinica B, 2024-01. Verfasst von Honglan Wang und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, the Chinese University of Hong Kong, Hong Kong SAR, China. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Research Grants Council, University Grants Committee.
Abstract (Originalsprache)
Predatory bacteriophages have evolved a vast array of depolymerases for bacteria capture and deprotection. These depolymerases are enzymes responsible for degrading diverse bacterial surface carbohydrates. They are exploited as antibiofilm agents and antimicrobial adjuvants while rarely inducing bacterial resistance, making them an invaluable asset in the era of antibiotic resistance. Numerous depolymerases have been investigated preclinically, with evidence indicating that depolymerases with appropriate dose regimens can safely and effectively combat different multidrug-resistant pathogens in animal infection models. Additionally, some formulation approaches have been developed for improved stability and activity of depolymerases. However, depolymerase formulation is limited to liquid dosage form and remains in its infancy, posing a significant hurdle to their clinical translation, compounded by challenges in their applicability and manufacturing. Future development must address these obstacles for clinical utility. Here, after unravelling the history, diversity, and therapeutic use of depolymerases, we summarized the preclinical efficacy and existing formulation findings of recombinant depolymerases. Finally, the challenges and perspectives of depolymerases as therapeutics for humans were assessed to provide insights for their further development.
Autor:innen und Institutionen
- School of Pharmacy, the Chinese University of Hong Kong, Hong Kong SAR, China.
- Emergency Medicine Clinical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, China.
- Department of Respiratory, Shenzhen University General Hospital, Shenzhen University Clinical Medical Academy, Guangdong 518055, China.
Förderung
- Research Grants Council, University Grants Committee
Zitieren
APA
Wang, H., Liu, Y., Bai, C., & Leung, S. S. Y. (2024). Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects. Acta Pharmaceutica Sinica B, 14(1), 155-169. https://doi.org/10.1016/j.apsb.2023.08.017
Vancouver
Wang H, Liu Y, Bai C, Leung SSY. Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects. Acta Pharmaceutica Sinica B. 2024;14(1):155-169. doi:10.1016/j.apsb.2023.08.017
BibTeX
@article{Wang2024,
author = {Wang, Honglan and Liu, Yannan and Bai, Changqing and Leung, Sharon Shui Yee},
title = {Translating bacteriophage-derived depolymerases into antibacterial therapeutics: Challenges and prospects},
journal = {Acta Pharmaceutica Sinica B},
year = {2024},
volume = {14},
number = {1},
pages = {155--169},
doi = {10.1016/j.apsb.2023.08.017}
}
EUVIMED